You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)附屬擬出售石藥中誠49.5%股權 繼續聚焦創新藥品研發及銷售業務
格隆匯 04-30 12:22

格隆匯4月30日丨石藥集團(01093.HK)宣佈,於2021年4月30日,公司非全資附屬石藥中諾(作為賣方)與石藥控股(作為買方)訂立股權轉讓協議,內容有關買賣石藥中誠的49.5%股權,代價為人民幣3465萬元。於出售事項完成後,集團將不再於石藥中誠擁有任何權益。

於2021年4月30日,石藥中誠結欠石藥中諾及集團其他成員公司貸款(連同累計利息及相關税項)合共約人民幣5.57億元(即該等貸款)。根據股權轉讓協議,石藥控股亦將向石藥中誠提供金額約為人民幣5.57億元的貸款,有關款項將用於悉數償還該等貸款。

出售事項的所得款項約為人民幣5.91億元(包括石藥中誠將予償還的該等貸款金額),經扣除所有相關開支、費用及税項後,將用於集團的一般營運資金用途。

公司表示,石藥中誠的現有業務盈利水平不高,而且,其未來戰略定位將集中在第三方物流、高端醫院及公寓租賃等,回報期相對較長,亦不符合集團的發展方向(即創新藥品)。出售事項可讓集團收回該等貸款,並將其資源集中於創新藥品研發及銷售的業務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account